Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flutafuranol F 18 - Navidea Biopharmaceuticals

Drug Profile

Flutafuranol F 18 - Navidea Biopharmaceuticals

Alternative Names: [18F]-AZD4694; [18F]-NAV4694; AZD-4694; NAV-4694

Latest Information Update: 28 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antidementias; Benzofurans; Fluorinated hydrocarbons; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Mild cognitive impairment

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 Flutafuranol F 18 - Navidea Biopharmaceuticals is available for licensing as of 31 Dec 2017. https://www.sec.gov/Archives/edgar/data/810509/000143774918004756/navb20171231_10k.htm
  • 16 Apr 2018 Flutafuranol F 18 is still in phase II trials for Mild cognitive impairment in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top